Study of the genetic variability of ZAC1 (PLAGL1) in French population-based samples

Journal of Hypertension

Volumn 27, Issue 2, 2009, Pages 314-321

  Goumidi, Louisa ^a,b,c   Spengler, Dietmar ^d   Cottel, Dominique ^a,b,c   Wagner, Aline ^e   Ducimetière, Pierre ^a,f   Ruidavets, Jean Bernard ^a,g   Legry, Vanessa ^a,b,c   Arveiler, Dominique ^e   Bingham, Annie ^a,f   Ferrières, Jean ^a,g   Amouyel, Philippe ^a,b,c   Meirhaeghe, Aline ^a,b,c  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c UNIV LILLE   (France)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^e Faculté de Mé decine   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN REGULATING APOPTOSIS AND CELL CYCLE ARREST PROTEIN; CELL CYCLE PROTEIN; PLAGL1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CC GENOTYPE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; EXTRACHROMOSOMAL INHERITANCE; FEMALE; FRANCE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; GROWTH RETARDATION; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIGENE FAMILY; PHENOTYPE; PHYSICAL ACTIVITY; PLAG GENE; PLEOMORPHIC ADENOMA; POPULATION GENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; ZAC1 GENE; ADULT; AGED; CAUCASIAN; GENETIC PREDISPOSITION; GENETICS; HYPERLIPIDEMIA; MIDDLE AGED;

ADULT; AGED; CELL CYCLE PROTEINS; DIABETES MELLITUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FRANCE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 63849101298     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831bc736     Document Type: Article

References (43)

1. Spengler D, Villalba M, Hoffmann A, Pantaloni C, Houssami S, Bockaert J, Journot L. Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. EMBO J 1997; 16:2814-2825.
2. Varrault A, Gueydan C, Delalbre A, Bellmann A, Houssami S, Aknin C, et al. Zac1 regulates an imprinted gene network critically involved in the control of embryonic growth. Dev Cell 2006; 11:711-722.
3. Hoffmann A, Ciani E, Boeckardt J, Holsboer F, Journot L, Spengler D. Transcriptional activities of the zinc finger protein Zac are differentially controlled by DNA binding. Mol Cell Biol 2003; 23:988-1003.
4. Bilanges B, Varrault A, Mazumdar A, Pantaloni C, Hoffmann A, Bockaert J, et al. Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities. Oncogene 2001; 20:1246-1253.
5. Huang SM, Stallcup MR. Mouse Zac1, a transcriptional coactivator and repressor for nuclear receptors. Mol Cell Biol 2000; 20:1855-1867.
6. Huang SM, Schonthal AH, Stallcup MR. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. Oncogene 2001; 20:2134-2143.
7. Hoffmann A, Barz T, Spengler D. Multitasking C2H2 zinc fingers link Zac DNA binding to coordinated regulation of p300-histone acetyltransferase activity. Mol Cell Biol 2006; 26:5544-5557.
8. Hoffmann A, Spengler D. A new coactivator function for Zac1's C2H2 zinc finger DNA-binding domain in selectively controlling PCAF activity. Mol Cell Biol 2008; 28:6078-6093.
9. Valente T, Auladell C. Expression pattern of Zac1 mouse gene, a new zinc-finger protein that regulates apoptosis and cellular cycle arrest, in both adult brain and along development. Mech Dev 2001; 108:207-211.
10. Valente T, Dominguez MI, Bellmann A, Journot L, Ferrer I, Auladell C. Zac1 is up-regulated in neural cells of the limbic system of mouse brain following seizures that provoke strong cell activation. Neuroscience 2004; 128:323-336.
11. Valente T, Junyent F, Auladell C. Zac1 is expressed in progenitor/stem cells of the neuroectoderm and mesoderm during embryogenesis: differential phenotype of the Zac1-expressing cells during development. Dev Dyn 2005; 233:667-679.
12. Kamiya M, Judson H, Okazaki Y, Kusakabe M, Muramatsu M, Takada S, et al. The cell cycle control gene ZAC/PLAGL1 is imprinted-a strong candidate gene for transient neonatal diabetes. Hum Mol Genet 2000; 9:453-460.
13. Arima T, Drewell RA, Arney KL, Inoue J, Makita Y, Hata A, et al. A conserved imprinting control region at theHYMAI/ZACdomain is implicated in transient neonatal diabetes mellitus. Hum Mol Genet 2001; 10:1475-1483.
14. Gardner RJ, Mackay DJ, Mungall AJ, Polychronakos C, Siebert R, Shield JP, et al. An imprinted locus associated with transient neonatal diabetes mellitus. Hum Mol Genet 2000; 9:589-596.
15. Ma D, Shield JP, Dean W, Leclerc I, Knauf C, Burcelin RR, et al. Impaired glucose homeostasis in transgenic mice expressing the human transient neonatal diabetes mellitus locus, TNDM. J Clin Invest 2004; 114:339-348.
16. Valleley EM, Cordery SF, Bonthron DT. Tissue-specific imprinting of the ZAC/PLAGL1 tumour suppressor gene results from variable utilization of monoallelic and biallelic promoters. Hum Mol Genet 2007; 16:972-981.
17. Polak M, Shield J. Neonatal and very-early-onset diabetes mellitus. Semin Neonatol 2004; 9:59-65.
18. Constancia M, Kelsey G, Reik W. Resourceful imprinting. Nature 2004; 432:53-57.
19. Charalambous M, da Rocha ST, Ferguson-Smith AC. Genomic imprinting, growth control and the allocation of nutritional resources: consequences for postnatal life. Curr Opin Endocrinol Diabetes Obes 2007; 14:3-12.
20. Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008; 359:61-73.
21. Barz T, Hoffmann A, Panhuysen M, Spengler D. Peroxisome proliferatoractivated receptor gamma is a Zac target gene mediating Zac antiproliferation. Cancer Res 2006; 66:11975-11982.
22. Halabi CM, Beyer AM, de Lange WJ, Keen HL, Baumbach GL, Faraci FM, Sigmund CD. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab 2008; 7:215- 226.
23. Yuasa S, Onizuka T, Shimoji K, Ohno Y, Endo J, Kanazawa H, et al. Zac1 is an essential cardiac transcription factor [Abstract]. Human Cell 2008; 21:A20.
24. Yuasa S, Onizuka T, Shimoji K, Ohno Y, Endo J, Kanazawa H, et al. Zac1 is an essential cardiac transcription factor [Abstract]. Circulation 2007; 116:129.
25. Yuasa S, Onizuka T, Shimoji K, Yohei O, Fukuda K, Ogawa S. Zac1 is an essential transcription factor for cardiac morphogenesis and cardiac myocyte apoptosis inhibition [Abstract]. J Card Fail 2008; 14:S154.
26. McGrath MF, de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab 2005; 16:469-477.
27. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21:733- 741.
28. Czubryt MP, Lamoureux L, Abrenica B. Zac1 is a transcriptional target of the muscle-enriched transcription factor mef2 [Abstract]. J Mol Cell Cardiol 2006; 40:871.
29. Yung CK, Halperin VL, Tomaselli GF, Winslow RL. Gene expression profiles in end-stage human idiopathic dilated cardiomyopathy: altered expression of apoptotic and cytoskeletal genes. Genomics 2004; 83: 281-297.
30. Barker DJ, Bagby SP, Hanson MA. Mechanisms of disease: in utero programming in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2:700-707.
31. Barker DJ. Adult consequences of fetal growth restriction. Clin Obstet Gynecol 2006; 49:270-283.
32. Dallongeville J, Delcroix AG, Wagner A, Ducimetiere P, Ruidavets JB, Arveiler D, et al. The APOA4 Thr347->Ser347 polymorphism is not a major risk factor of obesity. Obes Res 2005; 13:2132-2138.
33. Ecological analysis of the association between mortality and major risk factors of cardiovascular disease. The World Health Organization MONICA Project. Int J Epidemiol 1994; 23:505- 516.
34. Tregouet DA, Ricard S, Nicaud V, Arnould I, Soubigou S, Rosier M, et al. In-depth haplotype analysis of ABCA1 gene polymorphisms in relation to plasma ApoA1 levels and myocardial infarction. Arterioscler Thromb Vasc Biol 2004; 24:775-781.
35. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automated Control AC 1974; 19:716-723.
36. Gloyn AL, Mackay DJ, Weedon MN, McCarthy MI, Walker M, Hitman G, et al. Assessment of the role of common genetic variation in the transient neonatal diabetes mellitus (TNDM) region in type 2 diabetes: a comparative genomic and tagging single nucleotide polymorphism approach. Diabetes 2006; 55:2272-2276.
37. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308:1583-1587.
38. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension 2003; 41:207- 210.
39. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23:1038-1039.
40. Krushkal J, Ferrell R, Mockrin SC, Turner ST, Sing CF, Boerwinkle E. Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings. Circulation 1999; 99:1407-1410.
41. Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, et al. Genome-wide mapping of human loci for essential hypertension. Lancet 2003; 361:2118-2123.
42. Yang Q, Lai CQ, Parnell L, Cupples LA, Adiconis X, Zhu Y, et al. Genome-wide linkage analyses and candidate gene fine mapping for HDL3 cholesterol: the Framingham Study. J Lipid Res 2005; 46: 1416-1425.
43. Van Dyck F, Braem CV, Chen Z, Declercq J, Deckers R, Kim BM, et al. Loss of the PlagL2 transcription factor affects lacteal uptake of chylomicrons. Cell Metab 2007; 6:406-413.